JP2021535761A - ｓＰＤ−１バリアント−Ｆｃ融合タンパク質 - Google Patents

ｓＰＤ−１バリアント−Ｆｃ融合タンパク質 Download PDF

Info

Publication number
JP2021535761A
JP2021535761A JP2021539337A JP2021539337A JP2021535761A JP 2021535761 A JP2021535761 A JP 2021535761A JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021539337 A JP2021539337 A JP 2021539337A JP 2021535761 A JP2021535761 A JP 2021535761A
Authority
JP
Japan
Prior art keywords
spd
variant
domain
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535761A5 (https=
JPWO2020056085A5 (https=
Inventor
アマト ジェイ． ジアッシア
トッド エイ． アギレラ
ミハリス エス． カリオリス
ユー ミャオ
カウシク サッカール
シン エリック チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2021535761A publication Critical patent/JP2021535761A/ja
Publication of JP2021535761A5 publication Critical patent/JP2021535761A5/ja
Publication of JPWO2020056085A5 publication Critical patent/JPWO2020056085A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021539337A 2018-09-14 2019-09-12 ｓＰＤ−１バリアント−Ｆｃ融合タンパク質 Pending JP2021535761A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731488P 2018-09-14 2018-09-14
US62/731,488 2018-09-14
US201962888320P 2019-08-16 2019-08-16
US62/888,320 2019-08-16
PCT/US2019/050742 WO2020056085A1 (en) 2018-09-14 2019-09-12 Spd-1 variant - fc fusion proteins

Publications (3)

Publication Number Publication Date
JP2021535761A true JP2021535761A (ja) 2021-12-23
JP2021535761A5 JP2021535761A5 (https=) 2022-09-07
JPWO2020056085A5 JPWO2020056085A5 (https=) 2022-09-07

Family

ID=68211179

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539337A Pending JP2021535761A (ja) 2018-09-14 2019-09-12 ｓＰＤ−１バリアント−Ｆｃ融合タンパク質

Country Status (11)

Country Link
US (2) US11498955B2 (https=)
EP (1) EP3850003A1 (https=)
JP (1) JP2021535761A (https=)
KR (1) KR20210058902A (https=)
CN (1) CN112969710A (https=)
AU (1) AU2019338416A1 (https=)
CA (1) CA3109983A1 (https=)
NZ (1) NZ774126A (https=)
SG (1) SG11202101904UA (https=)
TW (2) TWI815964B (https=)
WO (1) WO2020056085A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
EP4243852A4 (en) * 2020-11-13 2024-12-11 Ludwig Institute for Cancer Research Ltd PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
EP4288080A1 (en) * 2021-02-04 2023-12-13 Helsingin Yliopisto A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto
US20240141014A1 (en) * 2021-03-03 2024-05-02 Shattuck Labs, Inc. Mutant pd-1 extracellular domains
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20250115657A1 (en) * 2021-05-28 2025-04-10 Akso Biopharmaceutical, Inc. Bispecific FC Fusion Proteins with sPD-1 and IL-15
WO2023048518A1 (ko) * 2021-09-24 2023-03-30 바이오엔시스템스 주식회사 Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121634A1 (en) * 2010-11-11 2012-05-17 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
WO2014124217A1 (en) * 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
WO2017055547A1 (en) * 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
JP2017525354A (ja) * 2014-08-08 2017-09-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｐｄ−１薬剤とその使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693504A1 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
EP3303383A1 (en) * 2015-06-05 2018-04-11 iBio, Inc. Endostatin fragments and variants for use in treating fibrosis
WO2017123548A1 (en) 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
WO2018104473A1 (en) * 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
US12065476B2 (en) * 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121634A1 (en) * 2010-11-11 2012-05-17 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
WO2014124217A1 (en) * 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
JP2017525354A (ja) * 2014-08-08 2017-09-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｐｄ−１薬剤とその使用方法
WO2016164428A1 (en) * 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
WO2017055547A1 (en) * 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions

Also Published As

Publication number Publication date
TW202023604A (zh) 2020-07-01
NZ774126A (en) 2023-05-26
SG11202101904UA (en) 2021-04-29
US20230131056A1 (en) 2023-04-27
AU2019338416A1 (en) 2021-04-29
US11498955B2 (en) 2022-11-15
TWI815964B (zh) 2023-09-21
CA3109983A1 (en) 2020-03-19
WO2020056085A1 (en) 2020-03-19
TW202348622A (zh) 2023-12-16
EP3850003A1 (en) 2021-07-21
US20200181231A1 (en) 2020-06-11
KR20210058902A (ko) 2021-05-24
CN112969710A (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
US20230131056A1 (en) sPD-1 VARIANT – FC FUSION PROTEINS
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
JP7273453B2 (ja) ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
US11524991B2 (en) PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
JP2021522175A (ja) Ｉｌ−１５／ｉｌ−１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
CN115768473A (zh) 靶向ox40和fap的双特异性抗原结合分子
AU2022358565A1 (en) Immunocytokine containing il-21r mutein
JP2023547506A (ja) Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
CN113004416B (zh) 靶向her2-cd137双特异性抗体的构建及其应用
RU2785993C2 (ru) ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC
HK40053326A (en) Spd-1 variant - fc fusion proteins
NZ796397A (en) sPD-1 variant - Fc fusion proteins
US20260103520A1 (en) Anti-cd3 antibodies and methods of use thereof
TW202444750A (zh) 抗pdl1單域抗體、融合蛋白及其用途
CN119451985A (zh) 在组合疗法中能够结合cd27的结合剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241021